UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering
August 17, 2022 23:04 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology Announces Proposed Public Offering of Common Stock
August 16, 2022 16:01 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates
August 12, 2022 07:05 ET
|
Unity Biotechnology, Inc.
- Announced Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection in subjects led to statistically significant and clinically meaningful...
UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
August 12, 2022 07:00 ET
|
Unity Biotechnology, Inc.
A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham...
UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME
August 11, 2022 17:45 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging,...
UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors
May 26, 2022 08:00 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today...
UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference
May 25, 2022 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging,...
UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases
May 05, 2022 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
March 15, 2022 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference
March 01, 2022 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...